Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).
Arantxa Romero-Toledo, PhD
Advertisement
Articles by Arantxa Romero-Toledo, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5